Contact Us
United States - English
China - 简体中文China - 繁體中文Germany – DeutschJapan - 日本語Switzerland - FrançaisUnited States - English

WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2016/10/21

WuXi AppTec Receives Inaugural “Company of the Year” Award from BayHelix

SHANGHAI, Oct. 21, 2016 --WuXi AppTec, a leading pharmaceutical, biotechnology, and medical device technology platform company, today announced that it has received the inaugural “Company of the Year” Award from BayHelix at a ceremony during the 3rd BioCentury China Healthcare Summit in Shanghai, China. The award is part of BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their achievement and contribution to the China healthcare ecosystem.

Read more

2016/08/15

WuXi AppTec’s STA Subsidiary Passed Third U.S. FDA Inspection

SHANGHAI, August 15, 2016 -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that the small molecule active pharmaceutical ingredient (API) and advanced intermediate manufacturing facility located in Jinshan Shanghai, which is part of its subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), recently successfully passed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration with no Form 483s issued. This is the third time that STA’s Jinshan facility passed the U.S. FDA inspection.

Read more

2016/08/08

WuXi AppTec’s STA Subsidiary Opens Operations in San Diego

SHANGHAI and San Diego, August 8, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego, which provides Process R&D and API manufacturing services for early phase clinical studies.

Read more

2016/08/01

WuXi AppTec’s Research Service Division Collaborates with Pelago Bioscience to Provide CETSA® based Target Engagement Assays

Stockholm, Münich, Shanghai, August 1, 2016 –WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its Research Service Division(RSD) will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA ®)method.

Read more

2016/05/12

WuXi AppTec’s Pharmaceutical Development Service and Analytical Service Passes EMA Inspection

Shanghai, May 12– WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its pharmaceutical facilities and analytical and stability testing facilities in Shanghai passed the European Medicines Agency (EMA)inspection for GMP compliance, with “no critical and no major findings.” This is the third consecutive time WuXi has passed the EMA inspection.

Read more